https://orcid.org/0000-0003-2062-1528
Figures
Abstract
Purpose
Coronary bioresorbable stents (BRS) do not produce blooming artifacts on computed tomography (CT), in contrast to metallic stents, as they are made of a bioresorbable polymer and are radiolucent. They allow to evaluate the coronary plaque beneath. The low-attenuation plaque (LAP) suggests plaque vulnerability and is CT assessable. The aim of our study was to show the possibility of a non-invasive CT evaluation of the volume and the LAP composition of the intra- and juxta-stent plaque.
Methodology
In our prospective longitudinal study, we recruited 27 consecutive patients (35 BRS stents total; mean age 60 +/- 9 years) with bioresorbable stents for a 256-slice ECG-synchronized CT evaluation at 1- and 12-months post stent implantation. Total plaque volume (mm3), absolute and relative (%) LAP volume per block in the pre- intra- and post-stent zones were analyzed; comparison 1- and 12-months post-implantation of BRS. Changes in the previously mentioned variables were assessed by the mixed effects models with and without spline, which also accounted for the correlation between repeated measurements.
Results
Our block or spline model analysis has shown no significant difference in plaque or absolute LAP volumes in pre- intra- and post-stent zones between 1 and 12 months. Interestingly, % LAP volume increases near-significantly in the distal block of the intrastent at 12-mo follow-up (from 23.38 ± 1.80% to 26.90 ± 2.22% (increase of 15%), p = 0.052).
Citation: Zdanovich E, Mansour S, Stevens L-M, Naim C, Juneau D, Semionov A, et al. (2022) Coronary bioresorbable stents: Non-invasive quantitative evaluation of intra- and juxta-stent plaque composition—A computed tomography longitudinal study. PLoS ONE 17(10): e0268456. https://doi.org/10.1371/journal.pone.0268456
Editor: Rudolf Kirchmair, Medical University Innsbruck, AUSTRIA
Received: July 24, 2021; Accepted: April 29, 2022; Published: October 13, 2022
Copyright: © 2022 Zdanovich et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The aim of our study is to demonstrate the feasibility of a noninvasive CT evaluation (dataset, author name: Evguenia Zdanovich, dataset title: “Liste patient REABSORB-CT - 8 août 2017_EZ”, data repository: Macintosh HD/Users/Eugenie/Documents/Maîtrise EZ/MAIN PROJECT/Liste des patients, version 2.0, year: 2017, global persistent identifier: created- August 8, 2017 at 3:36 PM) of volume and low-attenuation content of the intrastent coronary plaques, as well as plaques at the edges of the bioresorbable stents. The data is available from Dryad (https://doi.org/10.5061/dryad.wstqjq2pc).
Funding: Researc Grant, Abbott Laboratories for Dr Samer Mansour; Quebec Bio-Imaging Network funding for Dr Carl Chartrand-Lefebvre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Scaffold of coronary bioresorbable stents (BRS) is made of a bioresorbable polymer rather than metal. Once implanted in the artery, BRS progressively degrade and disappear within 2–3 years [1, 2]. BRS were developed to prevent permanent jailing of stented coronary segments, as it is the case with metallic stents, with the theoretical advantage of eventual normalization of adaptive vascular remodeling mechanisms [3]. Moreover, BRS do not produce significant artifacts on computed tomography (CT), in contrast to metallic stents [4–6]. BRS can be identified on CT by the platinum markers located at each extremity, while the rest of the stent is radiolucent [5]. Therefore, this novel scaffold platform allows noninvasive CT assessment of intrastent lumen, free of any metallic artefact.
In native coronary arteries, beyond the diagnosis of luminal stenosis, CT is useful for detection and volume quantification of atherosclerotic plaque. Furthermore, CT allows plaque characterization through identification of high-risk plaque features. Plaques can be characterized according to their CT attenuation by extraction of low-attenuation plaque content, i.e. lipid-content fraction, defined as attenuation values ≤ 30 Hounsfield units (HU). Low-attenuation plaque content has been associated with higher incidence of acute coronary events [7, 8].
In patients with metallic stents, intrastent imaging is performed using intracoronary invasive procedures, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) [9–12]. These techniques allow assessment of atherosclerotic lesion characteristics before stent implantation, as well as intrastent lumen and plaque evolution after implantation. However, blooming artifacts from metal struts [4] are precluding noninvasive CT imaging of intrastent plaques. We have hypothesized that CT can be effectively used for noninvasive assessment of the burden, high-risk features and evolution of intrastent atherosclerotic plaques in patients with BRS.
The aim of our study is to demonstrate the feasibility of a noninvasive CT evaluation ☯dataset, author name: Evguenia Zdanovich, dataset title: “Liste patient REABSORB-CT—8 août 2017_EZ”, data repository: Macintosh HD/Users/Eugenie/Documents/Maîtrise EZ/MAIN PROJECT/Liste des patients, version 2.0, year: 2017, global persistent identifier: created- August 8, 2017 at 3:36 PM] of volume and low-attenuation content of the intrastent coronary plaques, as well as plaques at the edges of the bioresorbable stents.
Materials and methods
Study design
This is a prospective cohort study that recruited consecutive patients with BRS for a 256-slice ECG-synchronized CT assessment at 1 and 12 months after stent implantation.
Ethical approval
The Institutional Review Board of the CHUM (Centre hospitalier de l’Université de Montréal) approved the protocol (approval 15.397). All subjects signed an informed consent form.
Study patients
The present study is part of in the ReABSORB registry [13]. ReABSORB is a prospective, nonrandomized, observational registry of 125 patients treated with an everolimus (Afinitor)-eluting BRS (ABSORBTM, version 1.1) at Centre Hospitalier de l’Université de Montréal in Montreal (CHUM) and Cité-de-la-Santé Hospital in Laval [13]. In the ReABSORB study, clinical follow-up was conducted at 1, 6, and 12 months, then yearly up to 4 years. The present study is a pilot study, nested in the ReABSORB registry. Sample of the pilot study was decided at 25 ReABSORB consecutive participants. The inclusion criteria of the present study were being a participant in the ReABSORB study, with 18 years of age and older. Exclusion criteria comprised renal impairment, adverse reaction to intravenous contrast agents and pregnancy. Twenty-seven consecutive patients were prospectively enrolled in the present study (36 BRS) (mean age 59.7 +/- 8.6 yo; 17 males, 59.3 +/- 8.9 yo; 10 females, 60.5 +/- 8.3 yo).
Two CT scans were planned for each patient, at 1 and 12 months after stent implantation, in order to occur as part of the predetermined clinical follow-up schedule. One-month scan was chosen as to be the closest to implantation. The 12-month follow-up scan was chosen in order to be comparable to time intervals from stent implantation reported in other studies [14], as well as to reduce loss to follow-up. Twenty-seven patients (35 stents) had a CT scan at 1-month post-intervention. Among those 27 patients, 21 (26 stents) were scanned a second time approximatively at 12 months post-implantation. Six patients of the initial 27 patients were not scanned at 12 months (4 patient refusal, 1 allergy to contrast agent, 1 incarcerated in jail) (Fig 1).
All participants were recruited consecutively from the ReABSORB registry. Six participants were excluded. A total of 27 participants underwent a CT evaluation, then 21 underwent a 12-month follow CT.
Stent implantation protocol.
BRS implantation was performed at the cardiologist’s discretion [13] and the following procedure was usually followed: (1) to select appropriate BRS size and adequate vessel preparation, vessel sizing was performed with QCA, OCT or IVUS; (2) a balloon at least 5 mm shorter than the chosen BRS length was deployed in predilation preparation, where balloon diameter was identical to the reference vessel diameter; (3) slow deployment of BRS, respecting reference vessel diameter, was conducted in 2-atm increments every 5 seconds until the BRS was completely deployed at a maximal pressure of 12–18 atm; and (4) to prevent BRS non-apposition, postdilation was performed with a noncompliant balloon with ≥0.25–0.5mm higher diameter than the BRS [13].
The struts of ABSORB BRS are made of bioresorbable poly-L-lactide and are 150-mm in width. Those struts are covered with a 7-mm layer of poly-D,L-lactide bioresorbable material and elute everolimus (Novartis, Basel, Switzerland). These stents were available since 2012 through a special access program and were approved for clinical practice in Canada since July 14, 2016 [13].
CT imaging
Patient preparation.
Prior to scan, patients received 0.4 mg nitroglycerin sublingually and 25–75 mg metoprolol per os, if their heart rate was > 60 beats per minute (bpm), unless contraindicated.
CT acquisition protocol.
All examinations were performed on a 256-slice CT scanner (Brilliance iCT, Philips Healthcare, Best, Netherlands). Prospective ECG-gating was used for heat rates ≤ 70 bmp and retrospective ECG-gating for higher heart rates.
Contrast administration protocol.
Patients received one of the following contrast agents: iopamidol (370 mg/mL, Isovue 370, Bracco Imaging, Montreal, Canada), iodixanol (320 mg/mL, Visipaque 320, GE Healthcare Canada Inc., Mississauga, Ontario, Canada); or iohexol (350 mg/ml, Omnipaque 350, GE Healthcare Canada Inc., Mississauga, Ontario, Canada) (Table 3). Contrast agent was administered with a power injector at a flow rate of 5 ml/sec.
CT image reconstruction and postprocessing.
Axial reconstruction was done using a medium-smooth kernel (XCB, Philips Healthcare, Cleveland, OH, USA) with a slice thickness of 0.8 mm. Iterative reconstruction (IR) was performed with a hybrid statistical algorithm (Philips iDose, Philips Healthcare, level 3). Post-processing of images was performed by TeraRecon (Aquarius Intuition version 4.4.12, TeraRecon Headquarters, Forster City, CA, USA).
CT imaging analysis
For coronary intra-stent and edge plaque analysis, 3 coronary zone locations were defined as follows: pre-, intra- and post-stent zones (Fig 2). Every zone was divided into blocks of 5 mm length following the long axis of the arteries. Pre-stent and post-stent zones were represented by one block each. The intra-stent zone had one to five blocks, depending on the length of the stent. The intra-stent block count started at the platinum indicator of the proximal stent edge and ended close to the indicator of the distal edge.
Pre-stent zone is the most proximal zone, while post-stent zone is the most distal. Bioresorbable stents also have 2 platinum indicators located at the extremities of the stent in the intrastent blocks numbered 1 and 5. 2016 © ☯Omar Arfa and Evguenia Zdanovich].
The coronary segments were described according to the nomenclature established by the American College of Cardiology/American Heart Association guidelines for coronary angiography 1999 [15].
Plaque analysis included total plaque volume (mm3), absolute LAP volume (mm3) and relative LAP volume (%) per block plaque volume in the pre-, intra- and post-stent zones. LAP was defined as plaque component with a <30 Hounsfield units (HU) CT attenuation. Relative LAP volume was defined as absolute LAP volume / total plaque volume (%). LAP volume was detected automatically by software in the 5-mm length coronary blocks following manual tracing of vessel contours (Fig 3). Image postprocessing was performed by a trained operator using a semi-automated software (Aquarius iNtuition 4.4.12, TeraRecon Inc, Foster City, CA, USA). Comparison of results was made between 1- and 12-month post-BRS implantation.
(A) Straightened MPR. There is stenosis at the proximal edge of the BRS in middle left anterior descending coronary artery. (B) Volumetric analysis of plaque HU-stratification. (Ci) Position within the plaque of the axial slice presented in views Cii and Ciii. (Cii) Axial view of lumen in Ci slice. (Ciii) Axial view of the mixed plaque with color-coded LAP and two spotty calcifications. (Di) Position within the plaque of axial slice presented in views Dii and Diii. (Dii) Axial view of lumen in Di slice. (Diii) Axial view of color-coded LAP plaque. (E) Histogram of the plaque composition stratification. LAP (9.19 mm3) represents one third of the total plaque volume (29.8 mm3). 2016 © ☯Omar Arfa and Evguenia Zdanovich].
The plaque analyses were performed at the same location in a given coronary artery for both 1- and 12-month scans.
Statistical analysis
Data was expressed as mean ± standard deviation or median [interquartile range] for continuous variables and frequency (%) for categorical variables. Mixed effects models were used to assess changes in total plaque volume and absolute or relative LAP volumes, and account for the correlation between repeated measurements (MIXED procedures in SAS software, version 9.4; SAS Institute, Cary, NC). Assessed coronary artery vessels and stented regions were divided in 3 zones (pre-stent, intra-stent, and post-stent). The intra-stent zone was further divided in 3 equidistant thirds using piecewise linear regression. P-values <0.05 were considered statistically significant.
Results
Study patients
The 27 patients had a total of 36 stented coronary artery segments: 25 (69%) in the left coronary artery, and 11 (31%) in the right coronary artery (Table 1). All scanned BRS could be assessed at about 1- and 12-month follow-up. One patient demonstrated an intra-stent stenosis in the LAD, at 12-month scan. This stenosis was subsequently dilated using an everolimus-eluting metallic stent (Fig 4). All other 35 stents were patent at the 1- and 12-month CT scans.
A). ECG-gated 256-slice coronary CT angiography 14 months after BRS implantation, in a 61-yo woman. An edge and intra-stent mixed plaque with severe stenosis and positive remodeling is shown (arrowhead). Proximal and distal platinum indicators of the BRS (2.5 x 18 mm) are also visible (arrows). 2016 © ☯Carl Chartrand-Lefebvre and Evguenia Zdanovich]. B) Conventional coronary angiography confirms severe intra-stent stenosis. The patient underwent stenting with an everolimus-eluting metallic stent in the same session. 2016 © ☯Samer Mansour].
Patient demographics and scanning parameters are described in Tables 2 and 3. Before BRS implantation, lesions were classified based on the ACC/AHA classification of coronary lesions [16]. There were 9 type A lesions (discrete, concentric lesion with smooth contours and absence of thrombus), 11 type B1 lesions and 8 type B2 lesions (lesion type B is tubular, eccentric with some thrombus potentially present, where subtype B1 is determined by one type B characteristic and subtype B2 by ≥2 characterictics), and 1 type C lesion (diffuse and high risk, and is present in tortuous and extremely angulated coronary segments) (Table 4). Most BRS had a length of 18 mm (47%) or 28 (47%) mm, with a mean length of 22.4 ± 5.6 mm (Table 5).
CT plaque analysis
Plaque analysis was performed on a per-block basis. There were 177 (88%, 177/201) assessable blocks at 1-month post-implantation out of a total of 201 blocks. For matched comparison at 12 months, 132 (66%, 132/201) blocks were assessable out of 201 blocks for a total of 309 block assessments (77%, 309/402) for both scans. Ninety-three (23%, 93/402) blocks were non-assessable for longitudinal imaging analysis. We were not able to assess all the blocks (93 blocks not assessed in total) for following reasons: absence of a second scan (6 patients, 11 stents, 51 blocks); absence of the first scan (1 patient, 1 stent, 7 blocks); stent overlap (4 patients, 10 stents, 21 blocks); image artefacts (8 patients, 8 stents, 9 blocks); blocks shorter than 5 mm (4 patients, 4 stents, 5 blocks).
Plaque volume analysis.
Plaque volume using the 5mm-long blocks model of segmentation. Table 6 shows mean plaque volume of the pre-, intra- and post-stent blocks after 1- and 12-month follow-up, according to the 5mm-long model of plaque segmentation. Intrastent block location is divided from proximal to distal blocks. There is a slight non-significant decrease in plaque volume from 1- to 12-month follow-ups in all locations. More distal plaques show greater decrease in volume in comparison to more proximal plaques, at 1- and 12-month follow-ups.
Plaque volume using the tertiles model of segmentation. Table 7 demonstrates plaque volume in the pre-, intra- and post-stent locations on 1- and 12-month scans. Intra-stent plaques are classified into proximal, median and distal tertiles. There is no significant change in plaque volumes from 1- to 12-month follow-ups in all locations.
LAP volume analysis.
LAP volume using the 5mm-long blocks model of segmentation. Table 8 shows mean LAP volume of pre-, intra- and post-stent blocks at 1- and 12-month follow-ups, according to the 5mm-long model of plaque segmentation. There is no significant change in LAP volume from 1- to 12-month follow-up in all locations.
LAP volume using the tertiles model of segmentation. Table 9 demonstrates LAP volume in the pre-, intra- and post-stent locations after 1- and 12-month scans, using the tertile model of segmentation for intra-stent plaque. There is no significant change in LAP volume from 1- to 12-month follow-up in all locations.
Relative LAP (%) analysis.
Relative LAP volume using the 5mm-long blocks model of segmentation. Table 10 shows mean ratio of LAP volume over total plaque volume (%) in the pre-, intra- and post-stent blocks after 1- and 12-month follow-up, according to the 5mm-long model of plaque segmentation. There is no significant change in relative LAP volume from 1- to 12 -month follow-up in all locations.
Relative LAP volume using the tertile model of segmentation. Table 11 demonstrates mean ratio of LAP volume over total plaque volume (%) in the pre- intra- and post-stent locations after 1- and 12-month scans, using the tertile model of segmentation for intra-stent plaque. There is no significant change in relative LAP volume from 1- to 12-month follow-up, although the slight increase in the distal intra-stent tertile is almost significant (p = 0.052).
There was no interaction between time and zone or block in any previously mentioned ANOVA analysis.
Discussion
The present study demonstrates the feasibility of noninvasive assessment of intrastent plaque volume and composition after BRS implantation using CT imaging. In this study, we prospectively recruited 27 patients with 36 coronary BRS for repeated assessment of intrastent and extrastent plaque volume and low attenuation component using CT angiography and plaque quantitative volumetric assessment, at 1 and 12 months from stent implantation. All stents were assessable with CT. Serial analyses were performed on 309 five-mm long intrastent and extrastent coronary wall blocks. Results will be discussed subsequently.
Multiple studies have contributed to the growing knowledge on native nonobstructive coronary artery atherosclerosis gained mostly from invasive techniques, namely intravascular ultrasound (IVUS) and optical coherence tomography (OCT), but also from noninvasive CT angiography. In a meta-analysis including 4733 subjects followed up for > 1 year, [17] Bamberg et al. showed that the presence of coronary plaque on CT was associated with a hazard ratio of 4.5 (95% confidence interval 2.2–9.3) for incident events (mostly cardiovascular), i.e. an approximately 4-fold increased risk compared to those without plaques on CT. In addition, more specific CT markers of plaque vulnerability, such as low attenuation plaque [7] and positive remodeling [7, 8], have been associated with increased prevalence [8] and incidence [7] of acute coronary syndrome. An ex vivo human study showed a good accuracy of CT angiography for the detection of coronary plaques with a lipid core, when compared to histological analysis and OCT [18]. In an in vivo study, plaques demonstrating low attenuation plaque and positive remodeling by CT angiography were associated with thin-cap fibroatheroma with macrophage infiltration on OCT [19].
In patients with coronary stents, coronary plaque imaging before as well as after stent implantation is also an important issue. In patients with metallic stents, intrastent plaque imaging is performed using intracoronary procedures (IVUS, OCT) [9–12]. In patients with metallic coronary stents, residual or growing intrastent plaque is directly adjacent to the blooming artifact from the struts and consequently, is not assessable in most cases.
In the ABSORB A Cohort trial, 25 patients with BRS were assessed using CT after 18-month follow-up [20], then reassessed at 60-month follow-up [14, 20]. The authors analyzed intrastent lumen patency, and they were able to assess intrastent lumen area and lumen volume. They also assessed intrastent atherosclerotic plaque volume [14]. A case report also showed that newer magnesium-based BRS could accurately be located using CT during follow-up, after scaffold strut resorption [21]. As shown in the present study, as well as in the study by Campos et al. [14], the BRS with metal-free scaffolds enable plaque CT imaging after stent implantation.
Our study used a prospective design and assessed intra- and extra-stent plaque volume in 27 patients after BRS implantation. In contrast to the study of Campos et al. [14], and for the first time, to our knowledge, we were also able to quantitatively assess, in addition to total plaque volume, the intrastent low attenuation plaque component.
Results explanation
Plaque volume and Absolute LAP volume.
In our CT study, plaque volumes in pre- intra- and post-stent were found to be similar at 1 and 12-month follow-ups. There is no established consensus in the literature as to how plaque area or volume evolves over time under the bioresorbable stent. Studies of plaque assessment under and juxta bioresorbable stent are mostly done with IVUS with follow-up ranging from 6 months to 5 years and portray contradictory results [14, 22–24]. Further CT studies are required to infirm or confirm our results.
Relative LAP volume.
Our study has also demonstrated that relative LAP increases (p = 0.052) in the distal intrastent tertile over time. In a study by Gogas et al. [25], patients with bioresorbable stents were investigated at 6 months (45 patients) and at 1-year (56 patients) follow-ups with virtual histology intravascular ultrasound (VH-IVUS) imaging. Gogas’ study demonstrated that at 1-year post-implantation, there was an increase in the relative fibrofatty tissue in 5-mm distal edge of the stent by 43.3% (p < 0.05) [25].
Of note, Pendyala et al. performed on 8 farm pigs with implanted 18 DES stents, superoxide production was found to be 55% more prominent in four distal millimeters rather than 4 proximal millimeters to the stents [26]. As excessive amount of superoxide can oxidize naturally circulating LDL in the blood, Rodríguez et al. states that the plaque formation increases with high oxidized LDL/ LDL ratio [27].
Clinical relevance
We believe that data obtained from studies assessing noninvasive CT imaging of bioresorbable stents, such as ours, is of particular importance. First, our results confirm that CT appears as an effective noninvasive imaging tool in patients with bioresorbable coronary stents, as shown by few groups up to now [14, 20]. Second, two recent meta-analyses [28, 29] showed ABSORB bioresorbable coronary stents to be associated with increased risk of stent thrombosis and target lesion failure (target vessel myocardial infarction and lesion revascularisation), in comparison to cobalt-chromium everolimus-eluting metallic stents. Despite these results, improvements can be expected from newer scaffold designs with thinner struts (125 μm and less) [30, 31], eluting drugs other than everolimus [32], dedicated implantation protocols [13], optimized lesion and patient selection, as well as modified antithrombotic therapy protocols [33]. In this context, feasibility of intrastent CT imaging makes the latter a valuable noninvasive tool for assessment of new BRS technologies.
Strengths and limitations
Our proof-of concept study is the first to analyze the relationship and progression of the intra- and juxta-BRS plaque and LAP volumes by CT scan. Nonetheless, our results should be hypothesis-generating as to the plaque progression mechanisms given the small sample size of our study.
Also, high-risk plaque features, other than its low attenuation component, were not assessed, such as positive remodeling. Furthermore, our CT findings (with one exception) were not correlated with invasive imaging, such as IVUS or OCT.
Conclusion
Our study confirms the feasibility of the repeated non-invasive quantitative assessment of the intrastent and juxta-stent coronary plaque by CT scan, in patients with bioresorbable stents. The developed method could be applied for the evaluation of different scaffold designs or pharmacological profiles of bioresorbable stents.
References
- 1. Brie D, Penson P, Serban M-C, Toth PP, Simonton C, Serruys PW, et al. Bioresorbable scaffold—A magic bullet for the treatment of coronary artery disease? Int. J. Cardiol. 215, 47–59 (2016).
- 2. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MWI, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371:899–907. pmid:18342684
- 3. Kereiakes DJ, Onuma Y, Serruys PW, Stone GW. Bioresorbable Vascular Scaffolds for Coronary Revascularization. Circulation 134, 168–182 (2016). pmid:27400899
- 4. Tan S, Soulez G, Diez Martinez P, Larrivée S, Stevens LM, Goussard Y, et al. Coronary Stent Artifact Reduction with an Edge-Enhancing Reconstruction Kernel—A Prospective Cross-Sectional Study with 256-Slice CT. PLoS One 11, e0154292 (2016). pmid:27128507
- 5. Gassenmaier T, Petri N, Allmendinger T, Flohr T, Maintz D, Voelker W, et al. Next generation coronary CT angiography: in vitro evaluation of 27 coronary stents. Eur. Radiol. 24, 2953–2961 (2014). pmid:25038859
- 6. Tanabe K, Popma JJ, Kozuma K, Saito S, Muramatsu T, Nakamura S, et al. Multi-slice Computed Tomography Assessment of Everolimus-Eluting Absorb Bioresorbable Scaffold in Comparison with Metallic Drug-Eluting Stents from the ABSORB Japan randomized Trial. EuroIntervention, 2018;14(9):1020–1028.
- 7. Motoyama S, Sarai M, Harigaya H, Anno H, Inoue K, Hara T, et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J. Am. Coll. Cardiol. 54, 49–57 (2009). pmid:19555840
- 8. Kitagawa T, Yamamoto H, Horiguchi J, Ohhashi N, Tadehara F, Shokawa T, et al. Characterization of noncalcified coronary plaques and identification of culprit lesions in patients with acute coronary syndrome by 64-slice computed tomography. JACC Cardiovasc. Imaging 2, 153–160 (2009). pmid:19356549
- 9. Brugaletta S, Radu MD, Garcia-Garcia HM, Heo JH, Farooq V, Girasis C, et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis 221, 106–112 (2012). pmid:22209268
- 10. Prati F, Romagnoli E, Gatto L, La Manna A, Burzotta F, Limbruno U, et al. Clinical Impact of Suboptimal Stenting and Residual Intrastent Plaque/Thrombus Protrusion in Patients With Acute Coronary Syndrome: The CLI-OPCI ACS Substudy (Centro per la Lotta Contro L’Infarto-Optimization of Percutaneous Coronary Intervention in Acute Coronary Syndrome). Circ. Cardiovasc. Interv. 9, (2016).
- 11. Qian J, Zhang F, Wu H, Fan B, Ge L, Ge J. Comparison of intravascular ultrasonic imaging with versus without incomplete stent apposition at follow-up after drug-eluting stent implantation. Int. J. Cardiovasc. Imaging 24, 133–139 (2008). pmid:17703294
- 12. Roleder T, Dobrolinska M, Pociask E, Wanha W, Smolka G, Walkowicz W, et al. Coronary plaque redistribution after stent implantation is determined by lipid composition: A NIRS-IVUS analysis. Cardiol J., 2020;27(3):238–245. pmid:30246238
- 13. Haddad K, Tanguay JF, Potter BJ, Matteau A, Gobeil F, Mansour S. Longer Inflation Duration and Predilation-Sizing-Postdilation Improve Bioresorbable Scaffold Outcomes in a Long-term All-Comers Canadian Registry. Can. J. Cardiol. 34, 752–758 (2018). pmid:29801740
- 14. Campos CM, Garcia-Garcia HM, Muramatsu T, de Araujo Gonçalves P, Onuma Y, Dudek D, et al. Impact of the Everolimus-eluting Bioresorbable Scaffold in Coronary Atherosclerosis. Revista espanola de cardiologia (English ed.) 69, 109–116 (2016). pmid:26739828
- 15. Morey SS. ACC and AHA update guidelines for coronary angiography. American College of Cardiology. American Heart Association. Am. Fam. Physician 60, 1017–1020 (1999).
- 16. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 82, 1193–1202 (1990). pmid:2401060
- 17. Bamberg F, Sommer WH, Hoffmann V, Achenbach S, Nikolaou K, Conen D, et al. Meta-analysis and systematic review of the long-term predictive value of assessment of coronary atherosclerosis by contrast-enhanced coronary computed tomography angiography. J. Am. Coll. Cardiol. 57, 2426–2436 (2011). pmid:21658564
- 18. Schlett CL, Maurovich-Horvat P, Ferencik M, Alkadhi H, Stolzmann P, Scheffel H, et al. Histogram analysis of lipid-core plaques in coronary computed tomographic angiography: ex vivo validation against histology. Invest. Radiol. 48, 646–653 (2013). pmid:23614976
- 19. Nakazato R, Otake H, Konishi A, Iwasaki M, Koo BK, Fukuya H, et al. Atherosclerotic plaque characterization by CT angiography for identification of high-risk coronary artery lesions: a comparison to optical coherence tomography. Eur. Heart J. Cardiovasc. Imaging 16, 373–379 (2015). pmid:25246503
- 20. Onuma Y, Dudek D, Thuesen L, Webster M, Nieman K, Garcia-Garcia HM, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv. 2013;6:999–1009. pmid:24156961
- 21. Pozo-Osinalde E, Gonzalo N, Salinas P. Follow-up evaluation of magnesium bioresorbable stent with computed tomography. J Cardiovasc Comput Tomogr. 2020;14:e75–e77. pmid:31088738
- 22. Serruys PW, Ormiston J, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, et al. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up. J. Am. Coll. Cardiol. 67, 766–776 (2016). pmid:26892411
- 23. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns RJ, de Bruyne B, et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 9, 1271–1284 (2014). pmid:24291783
- 24. Brugaletta S, Garcia-Garcia HM, Garg S, Gomez-Lara J, Diletti R, Onuma Y, et al. Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. Int. J. Cardiovasc. Imaging 27, 859–866 (2011). pmid:20941544
- 25. Gogas BD, Serruys PW, Diletti R, Farooq V, Brugaletta S, Radu MD, et al. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial. JACC Cardiovasc. Interv. 5, 656–665 (2012). pmid:22721662
- 26. Pendyala LK, Matsumoto D, Shinke T, Iwasaki T, Sugimoto R, Hou D, et al. Nobori stent shows less vascular inflammation and early recovery of endothelial function compared with Cypher stent. JACC Cardiovasc. Interv. 5, 436–444 (2012). pmid:22516402
- 27. Rodríguez M, Ringstad L, Schäfer P, Just S, Hofer HW, Malmsten M, et al. Reduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGb 761) in cardiovascular high-risk patients. Atherosclerosis 192, 438–444 (2007). pmid:17397850
- 28. Ali ZA, Serruys PW, Kimura T, Gao R, Ellis SG, Kereiakes DJ, et al. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet 390, 760–772 (2017). pmid:28732815
- 29. Kang SH, Gogas BD, Jeon KH, Park JS, Lee W, Yoon CH, et al. Long-term safety of bioresorbable scaffolds: insights from a network meta-analysis including 91 trials. EuroIntervention 13, 1904–1913 (2018). pmid:29278353
- 30. Tenekecioglu E, Serruys PW, Onuma Y, Costa R, Chamié D, Sotomi Y, et al. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging. JACC Cardiovasc. Interv. 10, 1115–1130 (2017).
- 31. Seth A, Onuma Y, Costa R, Chandra P, Bahl VK, Manjunath CN, et al. First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial. EuroIntervention 13, 415–423 (2017). pmid:28504218
- 32. Wang XZ, Zhang YJ, Fu GS, Jing QM, Xu B, Han YL. One-year clinical outcomes and multislice computed tomography angiographic results following implantation of the NeoVas bioresorbable sirolimus-eluting scaffold in patients with single de novo coronary artery lesions. Catheter. Cardiovasc. Interv. 91, 617–622 (2018). pmid:29392879
- 33. Capodanno D, Angiolillo DJ. Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds: A Review of the Published Data, Practical Recommendations, and Future Directions. JACC Cardiovasc. Interv. 10, 425–437 (2017). pmid:28279311